Physician profile
Ethan Lazarus
NPI 1427187962
$687,520.53
in general payments reported to CMS, 2019-2025
8 companies · $220K in 2025
The $220K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $36K · 2021: $65K · 2022: $57K · 2023: $73K · 2024: $155K · 2025: $220K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $295K · Consulting Fee: $88K · Travel and Lodging: $49K · Food and Beverage: $12K · Honoraria: $5,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $295,070.54 |
| Consulting Fee | $87,577.00 |
| Travel and Lodging | $48,744.00 |
| Food and Beverage | $11,593.30 |
| Honoraria | $5,426.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408,849.71 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $184,969.87 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49,419.11 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $35,098.23 | 2021-2025 | Contrave |
| Eli Lilly and Company | $8,661.38 | 2025 | |
| Nestle Healthcare Nutrition INC. | $305.25 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $197.90 | 2022-2025 | Imcivree |
| Nalpropion Pharmaceuticals LLC | $19.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Lazarus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.